TP53 and urinary bladder neoplasm: Masters et al (2003) suggest that the DO-7 anti-p53 antibody (Dako), used in the present study, is less strongly associated with pTa/pT1 bladder tumour progression than the alternative pAb1801 antibody (Novocastra).